Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Immunotherapy targeting PD-1/PD-L1 shows significant benefits in lung cancer. Cutaneous immune-related adverse events (irAEs) are frequent, early-developing side effects of ICIs, and their potential role as prognostic markers in non-small cell lung cancer (NSCLC) therapy requires further exploration.
Methods: Data of patients with NSCLC treated with camrelizumab Combined with chemotherapy were collected at Xuzhou Medical University from 2019 to 2023. Cutaneous irAEs were monitored using CTCAE v5.0, and therapeutic efficacy was assessed using RECIST 1.1 criteria for ORR and PFS. Multivariable Cox regression analysis identified independent predictors of PFS, and a nomogram was constructed to predict survival outcomes.
Results: Data from 151 patients were analyzed. Significant differences in the objective response rate (ORR, P = 0.016) and progression-free survival (PFS, P < 0.0001) were detected between NSCLC patients, either with cirAEs or not. Besides, PFS was significantly different in NSCLC patients who were subgrouped by the time of first cutaneous irAEs occurrence (P = 0.011), duration of cutaneous irAEs (P = 0.002), grade of cutaneous irAEs (P = 0.002), the number of cutaneous irAEs(P = 0.021). The multivariable analysis also revealed that cirAEs were positively associated with survival outcomes (HR: 0.316, 95% CI, 0.193- 0.519, P.0.001) for PFS. The nomogram was formulated based on the results of multivariate analysis and validated using an internal bootstrap resampling approach, which showed that the nomogram exhibited a sufficient level of discrimination according to the C-index 0.80 (95% CI, 0.748-0.850).
Conclusion: The presence of cirAEs in NSCLC patients treated with camrelizumab combined with chemotherapy is indicative of better treatment efficacy and prognosis. This study supports the utility of cirAEs as biomarkers for predicting the validity of immunotherapy in NSCLC. It proposes a novel, multi-parameter prognostic model to assess patient outcomes more accurately.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/0118715206350978241105080452 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Management of immune-related adverse events under PD-1/PD-L1 inhibitors: Insights from a Moroccan real-world experience.
Cancer Treat Res Commun
September 2025
Faculty of Medicine, Mohammed VI University of Health Sciences, Casablanca, Morocco.; Department of Medical Oncology, Cheikh Khalifa University Hospital, Casablanca, Morocco.; Department of Medical Oncology, Mohammed VI International University Hospital, Casablanca, Morocco. Electronic address: nism
Background: PD-1 and PD-L1 inhibitors, including pembrolizumab and atezolizumab, have improved survival outcomes in several malignancies. However, their use is frequently associated with immune-related adverse events (irAEs), which can pose management challenges, particularly in resource-limited settings like Morocco where real-world data remain scarce.
Objective: To characterize the incidence, spectrum, and severity of irAEs among Moroccan patients treated with pembrolizumab or atezolizumab, and to assess management approaches in light of ASCO and ESMO guidelines.
Histologic and immune characterization of cutaneous immune-related adverse events induced by immune checkpoint inhibitors.
J Immunother Cancer
August 2025
Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Background: Although immune checkpoint inhibitors (ICIs) are efficacious, they often cause immune-related adverse events (irAEs), most commonly cutaneous irAEs (CirAEs). The mechanisms underlying CirAEs remain unclear.
Methods: Attempting to better understand their mechanisms and histology we conducted a prospective study of 15 patients with advanced cancers treated with ICIs who developed grade 2 or higher CirAEs.
Severe oral and cutaneous immune-related adverse events induced by PD-1 inhibitors and antibody-drug conjugates: Case reports and management strategies.
Sci Prog
July 2025
Department of Oral Medicine, Peking University School and Hospital of Stomatology, Beijing, China.
With increased use of immune checkpoint inhibitors (ICIs) for treating tumors, immune-related adverse events (IrAEs) have risen. Severe cases of anti-PD-1 therapy-induced IrAEs such as Stevens-Johnson syndrome (SJS)-like and toxic epidermal necrolysis (TEN)-like lesions are rare but fatal. We report two cases of patients with malignant tumors who developed oral and cutaneous severe IrAEs: one induced by a PD-1 inhibitor alone and the other by a combination of a PD-1 inhibitor and an antibody-drug conjugates (ADCs).
View Article and Find Full Text PDFHistopathological and immunohistochemical features of cutaneous and oral immune-related adverse events associated with PD-1 inhibitor therapy.
Clin Exp Dermatol
July 2025
Department of Stomatology, São Paulo University, São Paulo, SP, Brazil.
Mucocutaneous reactions are among the most frequent and earliest immune-related adverse events (irAEs) secondary to programmed cell death protein 1 (PD-1) inhibitors treatment, often resembling autoimmune or immune-mediated disorders. Despite their prevalence, biopsies of irAEs are infrequently performed, resulting in limited data on their histopathological and immunohistochemical findings. We evaluated the histopathological and immunohistochemical features of irAEs in seven cancer patients treated with pembrolizumab (n = 5) or nivolumab (n = 2).
View Article and Find Full Text PDFNeurological immune-related adverse events with checkpoint inhibitor therapy: challenges for the neurologist.
J Neurol Neurosurg Psychiatry
July 2025
MRC Centre for Neuromuscular Diseases, National Hospital of Neurology and Neurosurgery, London, UK.
Immune checkpoint inhibitors (ICI) have had a dramatic effect on cancer outcomes with their use increasing as indications expand. Despite impressive efficacy across a range of tumour types, their role in activating the immune system results in frequent immune-related adverse events (irAE). While gastrointestinal, endocrine, respiratory and cutaneous toxicities are common, neurological irAEs (N-irAEs) occur more rarely.
View Article and Find Full Text PDF